Brief: In8bio's Inb-200 shows Extended Progression-Free Survival In Patients With Newly Diagnosed Glioblastoma

IN8bio

20/11/2023 12:28

Nov 20 (Reuters) - IN8BIO, Inc.  INAB.O :
    * IN8BIO’S INB-200 DEMONSTRATES EXTENDED PROGRESSION-FREE
SURVIVAL
IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    * IN8BIO, INC. - ALL PATIENTS TREATED WITH INB-200 WHO
COMPLETED
MANDATED DOSES TO DATE HAVE EXCEEDED A PROGRESSION-FREE SURVIVAL
(PFS) OF SEVEN MONTHS
    * IN8BIO, INC. - ADDITIONAL ENROLLED PATIENTS AWAIT DOSING
WITH
COMPLETION OF ENROLLMENT IN COHORT 3 EXPECTED IN 2023

Source text for Eikon:  ID:nGNX6hyNfH 
Further company coverage:  INAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))